R ecent, widely publicized incidents have highlighted continuing concerns that infections may be transmitted from patient to patient during routine flexible gastrointestinal endoscopic procedures (1) . Recognizing these concerns the Canadian Association of Gastroenterology (CAG) and the Public Health Agency of Canada (PHAC) collaborated in the development of a Canadian guideline for the reprocessing of gastrointestinal endoscopy equipment. Guideline development was facilitated by unrestricted grants from industry and support from the CAG and PHAC. High-quality processes to ensure infection prevention and control are essential components of the broader strategy to ensure delivery of safe endoscopy services as addressed in the recent CAG consensus guideline on safety and quality indicators in endoscopy (2) .
The Infection Control Guideline Steering Committee of PHAC develops national infection prevention and control guidelines to provide evidence-based recommendations to complement provincial/territorial governments' efforts in monitoring, preventing and controlling health care-associated infections. The PHAC infection prevention and control guideline for flexible gastrointestinal endoscopy and flexible bronchoscopy was published online in 2010 (3) . The guideline is intended to provide a comprehensive framework for the development of institution-specific policies and procedures for endoscopy facilities while ensuring that the critical elements and methods of cleaning, disinfection and/or sterilization of endoscopic devices are consistent with national standards. The United States Multi-Society document (4), published after the PHAC guideline, is broadly comparable in scope and content, as is the guideline by the Society of Gastroenterology Nurses and Associates (5, 6) . Scientific knowledge and medical technology are constantly evolving; therefore, the guideline is designed to be periodically updated. Research and revisions to keep pace with advances in the field are necessary and the expectation is that all reprocessing sites will maintain compliance with the most recent and applicable guideline. The current comprehensive guideline is intended to assist infection prevention and control professionals, and all other health care providers responsible for using and reprocessing flexible gastrointestinal endoscopes and flexible bronchoscopes in all settings where endoscopy is performed, whether in hospitals, clinics, physician offices or stand-alone endoscopy centres. Under the auspices of PHAC's Infection Control Guideline Steering Committee, an interdisciplinary Guideline Working Group, including clinical microbiologists, endoscopy nurses, gastroenterologists, hospital epidemiologists, infectious disease specialists, infection prevention and control professionals, biomedical technicians and representatives of the medical instrument reprocessing sector, was assembled to develop the guideline. This multidisciplinary group also reflected a balanced representation of the regions of Canada.
As a partner in the process, we (the CAG Endoscopy Committee) aim to provide practicing physicians with an executive summary of the guideline's contents. The guideline consists of seven sections, summarized below, which highlight the key elements relevant to infection prevention and control for flexible gastrointestinal endoscopy. For more comprehensive data and references, we encourage readers to review the original document available online (3).
SECtion 1: ADMiniStRAtivE RECoMMEnDAtionS
A robust administrative framework is essential for the successful adoption and implementation of effective infection prevention and control processes. Endoscopy facilities and, where appropriate, the overseeing health care facilities must be fully aware of the appropriate policiesthey should have detailed written policies and procedures that address all aspects of the handling (ie, cleaning, reprocessing and storage) of flexible endoscopes and accessories, which are consistent with current standards and recommendations.
• The endoscopy facilities' policies and procedures should specifically address the following: ○ Single-use equipment. ○ Responsibilities of management and staff involved in endoscopy service delivery. ○ The qualification, education and training requirements for all personnel handling endoscopes. ○ The responsibility of the endoscopist for notifying all involved personnel if there is any possibility of a transmissible infection (eg, tuberculosis, hepatitis, HIV, Clostridium difficile) even though universal precautions are promoted. ○ The recall of any improperly reprocessed equipment, evaluation of patient risk, notification of all affected individuals or institutions, and notification of appropriate regulatory bodies. ○ Regular review and revision, at least annually, of all policies and procedures, in collaboration with appropriate support programs.
• All health care facilities in which endoscopy is performed should have ongoing access to appropriate support programs, such as: ○ Infection prevention and control in health care facilities. ○ Occupational health and safety. ○ Personnel training and education in the handling of flexible endoscopes and accessories.
SECtion 2: RECoMMEnDAtionS foR EnDoSCoPy AnD EnDoSCoPy DEContAMinAtion EQuiPMEnt
The endoscopes, light sources and endoscopic accessories used every day in practice are essentially only the most visible part of what is required to appropriately equip an endoscopy unit.
• Medical equipment or devices intended for use in an endoscopy facility should be purchased only under the following circumstances: ○ They can be cleaned/reprocessed according to applicable, recommended standards. ○ They meet the requirements of the institution's infection prevention and control program. ○ They are fully supported by the manufacturer's provision of comprehensive information manuals on design, assembly, use, cleaning/reprocessing, staff training and audit processes for equipment handling.
• Maintenance and repair of medical equipment or devices intended for use in an endoscopy facility should be performed only by qualified personnel using original equipment manufacturer parts.
• Automatic endoscope reprocessors (AERs) should be purchased only if they meet the following criteria: ○ They are licensed for sale in Canada. ○ All endoscope channels and internal surfaces can be irrigated with high-level disinfectant or chemical sterilant. ○ They drain completely after each wash cycle, leaving no reservoirs. ○ Disinfectant is handled appropriately, with complete drainage between cycles for single-use disinfectant or daily monitoring, using appropriate test strips, for reusable disinfectant. ○ The manufacturer specifically identifies the brands and models of endoscopes and accessories that can be reprocessed effectively, as well as any potential limitations to reprocessing. ○ The manufacturers' reprocessing instructions for endoscopes and the AER have been compared and any conflicts resolved before the first reprocessing. ○ The manufacturer understands and meets its obligation to report any defect or circumstance that might affect endoscope reprocessing.
• The use of AERs should adhere to detailed, written policies and procedures to ensure that: ○ Any incomplete or interrupted AER cycle is repeated immediately. ○ Appropriate personnel associated with the endoscopy facility routinely review Health Canada's advisories, warnings, and recalls about marketed health products, Emergency Care Research Institute reports, manufacturer alerts and the scientific literature for reports of AER deficiencies that may lead to infection. ○ An endoscope that requires repairs must be disinfected properly or, if this is not possible, prepared and shipped appropriately as a contaminated instrument; only then should it be sent, in accordance with applicable jurisdictional requirements, to the repairer. ○ There are policies and processes for preventive maintenance of all devices and equipment.
SECtion 3: RECoMMEnDAtionS foR REPRoCESSinG EnDoSCoPES AnD ACCESSoRiES
The management of endoscope reprocessing requires strict regulation to ensure adequate cleaning and the avoidance of contamination of patients as well as other areas of the endoscopy unit. These steps must be audited regularly and adherence must be absolute. The steps involved have evolved over many years and are proven to be effective at avoiding contamination issues that may be catastrophic.
• Endoscopes should be wiped down immediately after a procedure.
• Channels should be flushed/brushed with enzymatic detergent and then flushed with water.
• Soiled endoscopes should be transported to the reprocessing area in a closed container.
• Leak testing should be performed according to manufacturer's requirements.
• All detachable components should be cleaned individually using enzymatic solution. • Endoscopes require high-level disinfection.
○ High-level disinfection is defined as the destruction of all vegetative microorganisms, mycobacteria, small or nonlipid viruses, medium or lipid viruses, fungal spores and some, but not all, bacterial spores.
• Instruments and accessories that break the mucosal barrier require sterilization. ○ Sterilization is defined as the destruction of all microbial life. • Formulations containing glutaraldehyde or glutaraldehyde with phenol/phenate (which require adequate ventilation in accordance with Workplace Hazardous Materials Information System and Ministry of Labour regulations), orthophthalaldehyde, hydrogen peroxide, peracetic acid, or a combination of hydrogen peroxide and peracetic acid can be used to achieve high-level disinfection if the products are used as directed.
• Manual processing is discouraged.
• Endoscopes should be stored uncoiled, hanging vertically in a clean, dry, ventilated area. ○ This prevents recontamination or damage. ○ The maximum allowable storage time before reprocessing is required is seven days.
• Strict adherence to manufacturer's requirements for reprocessors is critical for maintenance of appropriate high-level of disinfection. ○ As guidelines/requirements change, routine upgrading and reassessment of procedures are critical. ○ Only instruments specifically approved for cleaning in these reprocessors should be used.
• Health Canada approval is required for all sterilants or high-level disinfectants.
SECtion 4: RECoMMEnDAtionS foR EnDoSCoPy unit DESiGn
The development of any endoscopy unit must take into account not only patient 'flow' to maximize efficiency but also the 'flow' of endoscopes from 'clean to contaminated' areas.
• Any areas where endoscopes are used and disinfected should be designed to provide a safe environment for patients and health care workers. ○ Procedure rooms should have a separate, dedicated handwashing sink with hands-free controls. ○ Reprocessing areas should be provided with a separate hand washing station. ○ Workflow should proceed from 'clean to contaminated' areas, with adequate separation to minimize the risk of cross contamination. ○ Endoscope reprocessing areas should be physically separate from procedure rooms. ○ Clean, dry endoscope storage space is required, and should be physically separate from decontamination and cleaning areas.
• Preventing exogenous infections arising from microorganisms
introduced into the patient's body by the flexible endoscope, or by the accessories used in the procedure, must be of critical concern to every endoscopist. ○ The endoscopist's safety, as well as that of others involved in the procedure, must be protected.
SECtion 5: RECoMMEnDAtionS foR QuALity MAnAGEMEnt
Quality management encompasses all aspects of pre-and postprocedural care including the efficiency of the endoscopy unit and reprocessing area, as well as the endoscopic procedure itself.
• Personnel assigned to reprocess endoscopes and accessories should receive hands-on training with written, device-specific reprocessing instructions for every endoscope model and AER in their area of responsibility. ○ Competency should be documented by testing after completion of initial training and at least annually thereafter. ○ Personnel should not be allowed to reprocess endoscopes until competency is established.
○ The culture of the endoscopy unit should reflect the critical role the reprocessing personnel play in every procedure performed.
• Personal protective equipment (eg, gloves, gowns to be changed between procedures, eye protection visors and goggles) should be readily available and routinely used to protect health care workers and patients. ○ N 95 respirators should be used by health care workers present during the procedure if pulmonary or laryngeal tuberculosis is suspected.
• Endoscope and AER manufacturers' written recommendations and instructions for reprocessing should be followed.
• The disinfectant/sterilizing agent should be routinely tested to ensure minimum effective concentration of the active ingredient. ○ The solution should be checked at least at the beginning of each day and a log of test results maintained. ○ Regardless of the minimum effective concentration, the solution should be discarded at the end of its re-use life, which may be single use.
• There should be a standard protocol at each health care facility to enable users to easily identify the endoscopes that are ready for patient use and keep them separate from contaminated endoscopes.
• A surveillance system should be established to detect potential clusters of infections associated with endoscopic procedures.
• Permanent records of use and reprocessing of endoscopes should be maintained. ○ Records should include patient name, medical record number, the endoscopist, date and time of the clinical procedure, identification number and type of endoscope and AER, results of inspection and leak test and name of the person reprocessing the endoscope. ○ Records will aid in the investigation of any potential outbreaks associated with the endoscopic procedures and notification of the patients and health care providers (see Sections 6 and 7). ○ A record of preventive maintenance should be kept.
SECtion 6: RECoMMEnDAtion foR outBREAk invEStiGAtion AnD MAnAGEMEnt
Investigation and management of any potential outbreak of endoscopyrelated infection is essential to prevent further transmission and/or reoccurrence.
• If a breach in protocol for endoscope reprocessing is recognized, an assessment and investigation should be performed to determine why it occurred and how to prevent a recurrence. A risk assessment should be initiated to determine whether patient notification is required.
• If a cluster of suspected or confirmed endoscopy-related infections is identified, an investigation should be initiated to determine possible routes of transmission.
• A record should be kept of each endoscope used for each patient.
This is important for any future contact tracing when possible endoscopic disease transmission is being investigated. This should be a general policy.
SECtion 7: RECoMMEnDAtionS foR CLASSiC AnD vARiAnt CREutzfELDt-JAkoB DiSEASE
Unique management strategies, particularly for reprocessing, are required to prevent contamination by, and transmission of, some specific infections.
• Endoscopes used for invasive (eg, biopsy) procedures in individuals with possible variant Creutzfeldt-Jakob disease (vCJD) should be removed from use or quarantined to be reused exclusively on the same individual if required. If the diagnosis is positive for vCJD then the instrument should be incinerated.
○ Transmissible spongiform encephalopathy (TSE)-specific protein (pathological prion protein TSE) in vCJD is present in lymphatic tissue, which is prevalent in the gastrointestinal tract.
• With classic CJD, because pathological prion protein TSE has not been found in the gastrointestinal tract, gastrointestinal endoscopy alone is unlikely to be a vector for its transmission. However, if there is a risk that the endoscope could be contaminated with olfactory epithelium (neurological tissue), the endoscope should be removed from use.
• Aldehyde disinfectants should not be used to reprocess endoscopes that have been used in patients with (confirmed) classic CJD because they fix proteins.
• An instrument tracking record should be kept of each endoscope used for each patient. This is important for any future contact tracing when possible endoscopic disease transmission is being investigated. As noted in section 5, this should be a general policy.
